Abstract

The design of multifunctional polymer-based vectors, forming pDNA vaccines, offers great potential in cancer immune therapy. The transfection of dendritic immune cells (DCs) with tumour antigen-encoding pDNA leads to an activation of the immune system to combat tumour cells. In this work, we investigated the chemical attachment of DEC205 antibodies (aDEC205) as DC-targeting structures to polyplexes of P(Lys)-b-P(HPMA). The conjugation of a synthetic block copolymer and a biomacromolecule with various functionalities (aDEC205) requires bioorthogonal techniques to avoid side reactions. Click chemistry and in particular the strain-promoted alkyne-azide cycloaddition (SPAAC) can provide the required bioorthogonality. With regard to a SPAAC of both components, we firstly synthesized two different azide-containing block copolymers, P(Lys)-b-P(HPMA)-N3(stat) and P(Lys)-b-P(HPMA)-N3(end), for pDNA complexation. In addition, the site-specific incorporation of ring-strained dibenzocyclooctyne (DBCO) moieties to the DEC205 antibody was achieved by an enzymatic strategy using bacterial transglutaminase (BTG). The chemical accessibility of DBCO molecules within aDEC205 as well as the accessibility of azide-functionalities on the polyplex’ surface were investigated by various SPAAC experiments and characterized by fluorescence correlation spectroscopy (FCS).

Highlights

  • Within the field of nanomedicine, cancer therapy and diagnostics are the most active research areas [1,2,3,4,5]

  • The aim of this work was the selective, site-specific functionalization of DEC205 antibodies with dibenzocyclooctyne (DBCO) derivatives to allow bioorthogonal conjugation to pDNA polyplexes via strain-promoted alkyne-azide cycloaddition (SPAAC)

  • This bioconjugation strategy requires the introduction of azide moieties into the cationic block copolymer of P(Lys)-b-P(HPMA), used to condense polyanionic pDNA

Read more

Summary

Introduction

Within the field of nanomedicine, cancer therapy and diagnostics are the most active research areas [1,2,3,4,5]. Pathophysiological abnormalities of the tumour tissue, e.g., leaky vasculature and reduced lymphatic drainage, can lead to a passive accumulation of nanoparticles in these regions. EPR (enhanced permeability and retention) effect [6,7,8] can increase local drug concentrations at tumour site, while off-target effects can be effectively reduced. Tumour accumulation via EPR effect of nanomedicines highly depends on the nature of the tumour itself and may differ substantially among individual patients [8,10,11]. In comparison to the primary tumour, the treatment of tumour-derived metastasis provides another major challenge

Objectives
Results
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.